These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1143 related articles for article (PubMed ID: 25732842)

  • 1. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis.
    Emeršič A; Karikari TK; Kac PR; Gonzalez-Ortiz F; Dulewicz M; Ashton NJ; Brecl Jakob G; Horvat Ledinek A; Hanrieder J; Zetterberg H; Rot U; Čučnik S; Blennow K
    Mult Scler Relat Disord; 2024 Oct; 90():105801. PubMed ID: 39153429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Voortman MM; Stojakovic T; Pirpamer L; Jehna M; Langkammer C; Scharnagl H; Reindl M; Ropele S; Seifert-Held T; Archelos JJ; Fuchs S; Enzinger C; Fazekas F; Khalil M
    Mult Scler; 2017 Oct; 23(11):1496-1505. PubMed ID: 27899552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light chain level is a weak risk factor for the development of MS.
    Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M
    Neurology; 2016 Sep; 87(11):1076-84. PubMed ID: 27521440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
    Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis.
    Tamam Y; Gunes B; Akbayir E; Kizilay T; Karaaslan Z; Koral G; Duzel B; Kucukali CI; Gunduz T; Kurtuncu M; Yilmaz V; Tuzun E; Turkoglu R
    Mult Scler Relat Disord; 2021 Feb; 48():102697. PubMed ID: 33352356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
    Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
    Martínez-Yélamos A; Saiz A; Bas J; Hernandez JJ; Graus F; Arbizu T
    Neurosci Lett; 2004 Jun; 363(1):14-7. PubMed ID: 15157986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis.
    Momtazmanesh S; Shobeiri P; Saghazadeh A; Teunissen CE; Burman J; Szalardy L; Klivenyi P; Bartos A; Fernandes A; Rezaei N
    Rev Neurosci; 2021 Aug; 32(6):573-595. PubMed ID: 33594840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.